PMCB — Pharmacyte Biotech Balance Sheet
0.000.00%
- $6.12m
- -$10.64m
- 45
- 83
- 24
- 50
Annual balance sheet for Pharmacyte Biotech, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2020 April 30th | 2021 April 30th | 2022 April 30th | 2023 April 30th | 2024 April 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.895 | 2.2 | 85.4 | 68 | 50.2 |
| Prepaid Expenses | |||||
| Total Current Assets | 1.04 | 2.28 | 85.5 | 68.1 | 50.4 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 6.17 | 7.4 | 90.6 | 73.3 | 59.9 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.03 | 0.725 | 0.704 | 0.587 | 7.42 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1.08 | 0.725 | 0.704 | 0.587 | 20.4 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 5.09 | 6.68 | 89.9 | 72.7 | 39.5 |
| Total Liabilities & Shareholders' Equity | 6.17 | 7.4 | 90.6 | 73.3 | 59.9 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |